

EXPANDING OPTIONS FOR HIGH RISK OPERABLE EARLY-STAGE NSCLC PATIENTS

WORLD CONGRESS OF LUNG CANCER

Monday, July 4, 2011 | 07:00 – 08:00
Elicium I Conference Room

Amsterdam RAI Conference Centre
Amsterdam, The Netherlands

WCLC – Industry Sponsored Symposium

Registration required by June 30, 2011 | www.regonline.com/wclc2011

Attendance is complimentary. Online registration is required. Breakfast will be served.

PROGRAMME

06:30 – 07:00

Continental Breakfast and Reception

07:00 – 07:10

SUBLOBAR RESECTION VS SBRT FOR HIGH RISK OPERABLE S-1 NSCLC – BRIEF REVIEW

Harvey I. Pass, MD

New York University Langone Medical Center and Cancer Center, New York, NY

07:10 – 07:30

WASHINGTON UNIVERSITY TEAM: MOCK LUNG TUMOR BOARD CASES REVIEW

Bryan F. Meyers, MD, MPH and Jeffrey D. Bradley, MD

Washington University School of Medicine, St. Louis, MO, USA

07:30 – 07:50

VU UNIVERSITY TEAM: MOCK LUNG TUMOR BOARD CASES REVIEW

Marinus (Rick) A. Paul, MD, PhD and Suresh Senan, MRCP, RFCR, PhD

VU University Medical Center, Amsterdam, The Netherlands

07:50 – 08:00

PANEL DISCUSSION

Harvey I. Pass, MD

Moderator

FACULTY

MULTIDISCIPLINARY PANEL CHAIR

Harvey I. Pass, MD

Professor and Director, Division of Thoracic Surgery and Thoracic Oncology

New York University Langone Medical Center and Cancer Center, New York, NY

MULTIDISCIPLINARY THORACIC ONCOLOGY TEAM USA

Washington University School of Medicine, St. Louis, MO, USA

Bryan F. Meyers, MD, MPH

Professor and Chief of Thoracic Surgery

Jeffrey D. Bradley, MD

Associate Professor of Radiation Oncology and Chief of Thoracic Service

MULTIDISCIPLINARY THORACIC ONCOLOGY TEAM THE NETHERLANDS

VU University Medical Center, Amsterdam, The Netherlands

Marinus (Rick) A. Paul, MD, PhD

Chief, Division of General Thoracic Surgery, Department of Surgery

Suresh Senan, MRCP, RFCR, PhD

Professor of Clinical and Experimental Radiotherapy, Department of Radiation Oncology

SCAN THIS QR CODE TO GET THE WHITE PAPER



Scan this QR code to get the white paper, "Current Treatment of Early Stage Non-Small Cell Lung Cancer."

INQUIRIES

Lertora Williams
Varian Medical Systems, Inc.
Palo Alto, CA


Email: lertora.williams@varian.com

Phone: +1 650 424 6242

Nicole Leitch
Varian Medical Systems International AG
Zug, Switzerland

Email: info.europe@varian.com

Phone: +41 41 749 8582



take a closer look

Now there's an option for treating early-stage lung cancer patients with co-existing serious medical problems.

Following a median follow-up of 34.4 months, stereotactic body radiation therapy (SBRT) provided an estimated 3-year primary tumor control rate of 97.6% for 55 patients with non-small cell lung cancer who were unable to have the cancer surgically removed, according to a published multi-center RTOG study.*

To learn more visit us at **booth 511** or at www.varian.com/oncology/wclc2011

VARIAN
medical systems

A partner for **life**

*Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, Fakiris A, Bezjak A, Videtic G, Johnstone D, Fowler J, Gore E, Choy H.; Stereotactic Body Radiation Therapy For Inoperable Early Stage Lung Cancer; JAMA. 2010 Mar 17;303(11):1070-6.

Copyright © 2009-2011 Varian Medical Systems, Varian, and the Varian Medical Systems logo are registered trademarks of Varian Medical Systems, Inc.